Leading the Way in Life Science Technologies

GEN Exclusives

More »
Readers Comments Back to Item »

BAC Targeting Biosimilar Market

1 Readers' Comments

Posted by: Lester Savit

12/11/2011

In October a federal court blocked market entry of a generic version of a complex active ingredient because of a patent on manufacturing (quality) control.  See www.lestersavit.com for a discussion of how this ruling reveals a new patent strategy for biosimilars.

  • Click here to Login or to Register for free.

    You will be taken back to your selected item after Login/Registration.

Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »